This content is only available within our institutional offering.
25 Sep 2019
Pharmaceuticals: Hot topics at ESMO 2019
Novartis AG (0QLR:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Merck KGaA (MRCK:WBO), 0 | Sanofi (SANO:WBO), 0 | Valneva SE (0OB3:LON), 0 | AstraZeneca PLC (AZN:LON), 11,388 | GSK plc (GSK:LON), 1,654 | Ipsen SA (IPN:WBO), 0 | Novo Nordisk A/S Class B (NNO2:WBO), 0 | UCB S.A. (UCB:WBO), 0 | Bayer AG (BAYN:WBO), 0 | Basilea Pharmaceutica AG (0QNA:LON), 0
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Pharmaceuticals: Hot topics at ESMO 2019
Novartis AG (0QLR:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Merck KGaA (MRCK:WBO), 0 | Sanofi (SANO:WBO), 0 | Valneva SE (0OB3:LON), 0 | AstraZeneca PLC (AZN:LON), 11,388 | GSK plc (GSK:LON), 1,654 | Ipsen SA (IPN:WBO), 0 | Novo Nordisk A/S Class B (NNO2:WBO), 0 | UCB S.A. (UCB:WBO), 0 | Bayer AG (BAYN:WBO), 0 | Basilea Pharmaceutica AG (0QNA:LON), 0
- Published:
25 Sep 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
Pharmaceuticals
Hot topics at ESMO 2019
Presidential Symposiums: PARP inhibitors come first!
The end of the battle between GSK and AZ in BRCA non-mut. pts?
No groundbreaking news for PD-1/PD-L1s at the congress
Limited FV swing factors at first glance